Jacobs Levy Equity Management
SGMO

Jacobs Levy Equity Management’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

Jacobs Levy Equity Management’s Portfolio SGMO Stock Details SGMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$506K Buy
2,050,384
+999,670
+95% +$398K ﹤0.01% 827
2025
Q4 		$441K Buy
1,050,714
+204,181
+24% +$108K ﹤0.01% 819
2025
Q3 		$570K Hold
846,533
– – ﹤0.01% 801
2025
Q2 		$458K Sell
846,533
-451,252
-35% -$268K ﹤0.01% 895
2025
Q1 		$851K Buy
1,297,785
+555,323
+75% +$588K ﹤0.01% 840
2024
Q4 		$757K Sell
742,462
-729,255
-50% -$1.33M ﹤0.01% 755
2024
Q3 		$1.27M Sell
1,471,717
-1,479,227
-50% -$1.08M ﹤0.01% 682
2024
Q2 		$1.06M Buy
2,950,944
+2,758,995
+1,437% +$1.49M ﹤0.01% 729
2024
Q1 		$129K Sell
191,949
-816,113
-81% -$592K ﹤0.01% 909
2023
Q4 		$548K Buy
1,008,062
+604,280
+150% +$279K ﹤0.01% 816
2023
Q3 		$242K Buy
403,782
+195,734
+94% +$210K ﹤0.01% 900
2023
Q2 		$270K Sell
208,048
-313,943
-60% -$429K ﹤0.01% 895
2023
Q1 		$919K Buy
521,991
+404,467
+344% +$1.15M 0.01% 716
2022
Q4 		$369K Sell
117,524
-12,265
-9% -$47.6K ﹤0.01% 836
2022
Q3 		$636K Buy
129,789
+30,779
+31% +$158K 0.01% 796
2022
Q2 		$410K Buy
+99,010
New +$428K ﹤0.01% 892
2018
Q1 		– Sell
-40,540
Closed -$665K – 1053
2017
Q4 		$665K Buy
40,540
+9,200
+29% +$137K 0.01% 699
2017
Q3 		$470K Buy
+31,340
New +$346K 0.01% 715

Other funds holding SGMO

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

Jacobs Levy Equity Management's SGMO Position: Q1 2026 in Review

Jacobs Levy Equity Management increased its SANGAMO THERAPEUTICS INC (SGMO) stake by 95% in Q1 2026, buying an estimated $398K and bringing the position to 2,050,384 shares worth $506K. The position accounts for ﹤0.01% of the portfolio, ranked #827.

Jacobs Levy Equity Management first reported a position in SGMO in Q3 2017 and has held it in 18 quarters since. The position peaked at $1.27M in Q3 2024. 112 funds tracked by Wall St. Rank hold SGMO as of Q1 2026.

  • Jacobs Levy Equity Management held 2,050,384 shares of SANGAMO THERAPEUTICS INC worth $506K as of Q1 2026.
  • Jacobs Levy Equity Management bought 999,670 SANGAMO THERAPEUTICS INC shares in Q1 2026, an estimated $398K.
  • SANGAMO THERAPEUTICS INC made up ﹤0.01% of Jacobs Levy Equity Management's portfolio in Q1 2026, its #827 holding.
  • Jacobs Levy Equity Management first reported a position in SANGAMO THERAPEUTICS INC in Q3 2017 and has held it in 18 quarters since.
  • Jacobs Levy Equity Management's SANGAMO THERAPEUTICS INC position peaked at $1.27M in Q3 2024.
  • 112 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q1 2026.

Based on Jacobs Levy Equity Management's 13F filing for Q1 2026, filed 15 May 2026.